Comparison of valsartan with candesartan on their possible protection from atherosclerosis

Journal of Clinical and Basic Cardiology

Volumn 4, Issue 4, 2001, Pages 297-299

  Mueck, A O ^a   Seeger, H ^a   Heuberger, W ^a   Wallwiener, D ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Angiotensin II; Atherogenesis; Candesartan; Valsartan

Indexed keywords

ANGIOTENSIN; CANDESARTAN; ENDOTHELIN; ENZYME PRECURSOR; INTERSTITIAL COLLAGENASE; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; VALSARTAN;

ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

EID: 0035696052     PISSN: 15612775     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Angiotensin receptors and their antagonists
2. Nitric oxide: Mediator, murderer, and medicine
3. Endothelins
4. Plasminogen-activator inhibitor type 1 and coronary artery disease
5. Evidence for increased collagenolysis by interstitial collagenases 1 and 3 in vulnerable human atheromatous plaques
6. The pathogenesis of atherosclerosis - An update
7. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist
8. Candesartan cilexetil: A review of its preclinical pharmacology